Market closedNon-fractionalADR
Genmab/GMAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Genmab
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Ticker
GMAB
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Koebenhavn v, Denmark
Employees
2,286
Website
www.genmab.com
Genmab Metrics
BasicAdvanced
$19B
Market cap
23.41
P/E ratio
$1.20
EPS
0.98
Beta
-
Dividend rate
Price and volume
Market cap
$19B
Beta
0.98
52-week high
$42.72
52-week low
$26.32
Average daily volume
10
Financial strength
Current ratio
12.457
Quick ratio
12.419
Long term debt to equity
2.825
Total debt to equity
3.108
Management effectiveness
Return on assets (TTM)
16.25%
Return on equity (TTM)
18.27%
Return on investment (TTM)
17.48%
Valuation
Price to earnings (TTM)
23.413
Price to revenue (TTM)
7.201
Price to book
3.886
Price to tangible book (TTM)
3.939
Price to free cash flow (TTM)
23.872
Growth
Revenue change (TTM)
16.71%
Earnings per share change (TTM)
5.08%
3-year revenue growth (CAGR)
17.67%
3-year earnings per share growth (CAGR)
-2.94%
What the Analysts think about Genmab
Analyst Ratings
Majority rating from 10 analysts.
Genmab Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
kr 4.1B
-11.44%
Net income
kr 1.3B
107.03%
Profit margin
31.98%
133.77%
Genmab Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.30
$0.47
$0.14
$0.29
-
Expected
$2.18
$3.14
$3.26
$0.14
$0.33
Surprise
-86.20%
-84.96%
-95.70%
110.00%
-
Genmab News
AllArticlesVideos
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024
GlobeNewsWire·1 week ago
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
Business Wire·4 weeks ago
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Genmab stock?
Genmab (GMAB) has a market cap of $19B as of July 27, 2024.
What is the P/E ratio for Genmab stock?
The price to earnings (P/E) ratio for Genmab (GMAB) stock is 23.41 as of July 27, 2024.
Does Genmab stock pay dividends?
No, Genmab (GMAB) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Genmab dividend payment date?
Genmab (GMAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Genmab?
Genmab (GMAB) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Genmab stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.